Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M

DYADIC INTERNATIONAL INC

Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.
Revenue fell to $3.09M from $3.50M; net loss widened to $7.36M ($0.23/sh) from $5.81M ($0.20/sh).
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant; Dyadic eligible for profit share.
Expanded Fermbox Bio collaboration; commercial launch of recombinant DNase I (RNase-free).
OEM distribution agreement with IBT Bioservices for DNase I and transferrin; BRIG Bio deal for alpha-lactalbumin.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.